Quest Diagnostics Inc. (NYSE: DGX) reported first‑quarter 2026 results that surpassed Wall Street expectations, with total revenue of $2.90 billion, up 9.2% year‑over‑year, and diluted earnings per share of $2.50, beating the consensus estimate of $2.37. The company’s Diagnostic Information Services segment generated $2.83 billion, a 9.4% increase, driven by a 10.8% rise in requisition volume but a 1.3% decline in revenue per requisition, reflecting a shift toward higher‑margin advanced tests.
Operating income rose to $447 million, or 15.4% of net revenues, an improvement over the prior year’s 15.3% margin. The margin expansion was largely attributable to productivity gains from automation and artificial‑intelligence initiatives that offset modest cost increases, while the higher mix of advanced diagnostics helped lift profitability.
Management raised its full‑year 2026 revenue outlook to $11.78 billion–$11.90 billion, up from the previous $11.70 billion–$11.82 billion range, and lifted adjusted diluted EPS guidance to $10.63–$10.83, a 15–20% increase from the prior $10.50–$10.70 range. The upward revision signals confidence that the company’s demand‑side momentum and cost‑control programs will sustain growth throughout the year.
Jim Davis, Chairman, CEO and President, said, "Our more than 9% revenue growth, almost entirely organic, and approximately 13% adjusted diluted earnings per share growth reflect our team's disciplined execution of our strategy to deliver innovative diagnostic solutions for our customers' evolving needs." He added, "We are raising our revenue and EPS guidance for the year, given our robust first quarter performance and continued strategic focus."
The company also highlighted that its Alzheimer’s testing program more than doubled year‑over‑year, underscoring the impact of its advanced diagnostics portfolio. While the firm faces headwinds such as reimbursement pressure and rising labor costs, the continued demand for routine testing and the expansion of its consumer‑channel platform provide a solid tailwind that supports the revised outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.